CDK2 and prostate carcinoma: However, a recent publication points to the accumulation of CDK1 and CDK2 in RAD001-resistant prostate cancer cells (Tsaur et al, 2011), which supports our hypothesis that the reduction of α5 evoked by long-term RAD001 exposure may cause an increase in tumour growth.